GTBP News and Press, GT Biopharma Inc. From 11/10/22

Poster #1: Tri-specific killer engagers target natural killer cells towards mesothelioma Poster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) BRISB...

BRISBANE, CALIFORNIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK...

GT Biopharma press release ( NASDAQ: GTBP ): Q3 GAAP EPS of -$0.22 misses by $0.11 . $20.8 million in cash, cash equivalents and short-term investments as of September 30, 2022, is expected to provide runway to fund operations into 2023. For further details see: ...

Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) $20.8 million in cash, cash equivalents and short-term investments as of September 30, 2022, is expected to provide runway to fund operations into 2023. BRISBAN...

Brisbane, California--(Newsfile Corp. - October 25, 2022) - GT Biopharma, Inc.  ( NASDAQ: GTBP ) (the "Company" or "GTB"), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE &#x...

GT Biopharma ( NASDAQ: GTBP ) has filed for a $150M mixed shelf offering . The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for general corporate purposes. The offering can...

BRISBANE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) ce...

- Meeting adjourned to October 10, 2022 at 11 a.m. PST - GTB encourages all stockholders of record on August 8, 2022 who have not yet voted - to do so by 11:59 p.m. PST Time on October 9, 2022 BRISBANE, CALIFORNIA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the ȁ...

GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 alone GTB-5550 specifically targets B7-H3+ cells GTB-5550 effectively induced NK cell degranulation and interferon gamma production in response to various prostate, brain tumor (atypical rhabdo...

BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that...